Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;35 Suppl(0):S78-S103.
doi: 10.1016/j.semcancer.2015.03.001. Epub 2015 Apr 28.

Broad targeting of resistance to apoptosis in cancer

Ramzi M Mohammad  1 , Irfana Muqbil  2 , Leroy Lowe  3 , Clement Yedjou  4 , Hsue-Yin Hsu  5 , Liang-Tzung Lin  6 , Markus David Siegelin  7 , Carmela Fimognari  8 , Nagi B Kumar  9 , Q Ping Dou  10 , Huanjie Yang  11 , Abbas K Samadi  12 , Gian Luigi Russo  13 , Carmela Spagnuolo  13 , Swapan K Ray  14 , Mrinmay Chakrabarti  14 , James D Morre  15 , Helen M Coley  16 , Kanya Honoki  17 , Hiromasa Fujii  17 , Alexandros G Georgakilas  18 , Amedeo Amedei  19 , Elena Niccolai  19 , Amr Amin  20 , S Salman Ashraf  21 , William G Helferich  22 , Xujuan Yang  22 , Chandra S Boosani  23 , Gunjan Guha  24 , Dipita Bhakta  24 , Maria Rosa Ciriolo  25 , Katia Aquilano  25 , Sophie Chen  26 , Sulma I Mohammed  27 , W Nicol Keith  28 , Alan Bilsland  28 , Dorota Halicka  29 , Somaira Nowsheen  30 , Asfar S Azmi  2
Affiliations
Review

Broad targeting of resistance to apoptosis in cancer

Ramzi M Mohammad et al. Semin Cancer Biol. 2015 Dec.

Abstract

Apoptosis or programmed cell death is natural way of removing aged cells from the body. Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks to eliminate malignant cells. However, in cancer, de-regulated apoptotic signaling, particularly the activation of an anti-apoptotic systems, allows cancer cells to escape this program leading to uncontrolled proliferation resulting in tumor survival, therapeutic resistance and recurrence of cancer. This resistance is a complicated phenomenon that emanates from the interactions of various molecules and signaling pathways. In this comprehensive review we discuss the various factors contributing to apoptosis resistance in cancers. The key resistance targets that are discussed include (1) Bcl-2 and Mcl-1 proteins; (2) autophagy processes; (3) necrosis and necroptosis; (4) heat shock protein signaling; (5) the proteasome pathway; (6) epigenetic mechanisms; and (7) aberrant nuclear export signaling. The shortcomings of current therapeutic modalities are highlighted and a broad spectrum strategy using approaches including (a) gossypol; (b) epigallocatechin-3-gallate; (c) UMI-77 (d) triptolide and (e) selinexor that can be used to overcome cell death resistance is presented. This review provides a roadmap for the design of successful anti-cancer strategies that overcome resistance to apoptosis for better therapeutic outcome in patients with cancer.

Keywords: Apoptosis; Apoptosis evasion; Autophagy; Necrosis; Nuclear transporters, natural chemopreventive agents.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The apoptosis pathway: (A) The different paths that a cell can take during the activation of cell death. (B) Apoptosis can be triggered either by external receptor-dependent stimulus (extrinsic) or through internal (intrinsic) mitochondria-mediated signaling. The extrinsic pathway is initiated by the attachment of death receptors with their death initiating ligands, such as FASL, TRAIL or TNF. Consequently, an adaptor molecule, FADD also known as FAS-associated death domain protein, couples the death receptors and this subsequently leads to the activation of caspase-8. Activated caspase-8 can either directly cleave and activate caspase-7 or caspase-3, thereby promoting apoptosis. On the other hand the intrinsic pathway is modulated by the activation of BH3-only proteins sensing different types of cell stress, such as DNA damage or ER stress, and then activating BAX/BAK at mitochondrial outer membrane (MOM). MOM permeabilization (MOMP) leads to release of different apoptosis-mediating molecules, such as cytochrome c, which activates caspase-9. In turn, caspase-9 cleaves and activates caspase-3 and caspase-7, thus triggering apoptotic cell death. Both pathways interface at the point of caspase-3 activation. The formation of autophagosome formation requires activation of Beclin 1 which acts as a component of a multiprotein (PI3K) complex. The crosstalk between autophagy and apoptosis is mediated at least in part by the functional and structural interaction between Beclin 1 and the anti-apoptotic proteins BCL-2 and BCL-XL. Diverse apoptotic stimuli either intrinsic or extrinsic can lead to caspase-mediated cleavage of Beclin 1 rendering it ineffective as an autophagy inducer. The master tumor suppressor p53 has essential roles in both apoptosis and autophagy. At the transcriptional level, p53 upregulates BAX, PUMA and BID or reduces the expression of BCL-2, which antagonizes BAX. In addition to apoptosis, p53 can also induce autophagy through TOR inhibition and also through transcriptional activation of DRAM.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546–58. - PMC - PubMed
    1. Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, et al. Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. Cancer. 2014;120:181–9. - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. - PubMed
    1. Du TA. Cell death: balance through a bivalent regulator. Nat Rev Mol Cell Biol. 2013;14:546. - PubMed
    1. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 1993;4:327–32. - PubMed

Publication types

Substances